# OnCo record nct07069712 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07069712/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07069712", "NCT07069712" ;
  schema:name "A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma"@en ;
  schema:alternateName "GEMINI-PeriOp GC"@en ;
  schema:description "A phase 2 trial of Sonesitatug vedotin, Rilvegostomig, Trastuzumab, Trastuzumab deruxtecan, Capecitabine and Fluorouracil (5-FU) in oesophageal cancer, run by AstraZeneca, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07069712/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07069712> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2025-07-17" ;
  onco:cancers <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/oesophageal-adenocarcinoma/> ;
  onco:drugs <https://onco.cc/drugs/cmg901/>, <https://onco.cc/drugs/rilvegostomig/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/fluorouracil/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/parexel/> .